FDA asks Texas court to shut down 19 vaccine records lawsuit
Adds comment from FDA, plaintiff in paragraphs 7-9
By Mike Scarcella
Oct 18 (Reuters) -The U.S. Food and Drug Administration has asked a federal judge in Texas to throw out a public records lawsuit related to COVID-19 vaccines, arguing that it has already spent more than $3.5 million to produce more than 1 million documents in the case.
The FDA in a filing on Thursday defended the adequacy of the records it provided in the lawsuit, which was filed by scientists who wanted to see licensing information that the agency relied on to approve the Pfizer-BioNTech coronavirus vaccine.
The lawsuit, filed in late 2021, attracted widespread attention after the FDA said early on that it could take decades to process and disclose records to Public Health and Medical Professionals for Transparency, the group that brought the case.
The public records lawsuit said that “the medical and scientific community and the public have a substantial interest in reviewing the data and information underlying the FDA’s approval of the Pfizer Vaccine.”
It said the requested data would help resolve questions about the FDA’s review process.
U.S. District Judge Mark Pittman in an order in early 2022 set an accelerated time frame for the FDA, calling the group's Freedom of Information Act request an issue “of paramount public importance.”
The FDA declined to comment.
Aaron Siri, a lawyer for Public Health and Medical Professionals for Transparency, in a statement on Friday said the fight for records was not over.
“Despite years of litigation, and the Court’s order to produce all clinical trial documents, FDA continues to improperly withhold over a million pages of trial documents," Siri said.
The agency at one point was producing 55,000 pages of records every 30 days in response to court orders in the lawsuit. It said in Thursday's filing seeking to close the case that it set up “unprecedented and extraordinary operations” to comply with Pittman’s directives.
Public Health and Medical Professionals for Transparency, whose members include professors and scientists from Yale, Harvard, UCLA and Brown, has posted thousands of records on its website.
Lawyers for the group said in a recent court filing that they would waive any further challenge to redactions that the FDA made in the more than 1.2 million documents released as part of the lawsuit.
The adequacy of the FDA’s search for records is the remaining contested issue in the lawsuit.
The FDA said it conducted a “reasonable and adequate search for responsive records.” The group is due to respond to the FDA by Nov. 7.
The case is Public Health and Medical Professionals for Transparency v. U.S. Food and Drug Administration, U.S. District Court for the Northern District of Texas, No. 4:21-cv-01058-P.
For plaintiff: Aaron Siri and ElizabethBrehm of Siri & Glimstad
For defendant: Andrew Freidah of the U.S. Justice Department
Read more:
Pfizer pushes to intervene in lawsuit seeking COVID vaccine information from FDA
‘Paramount importance’: Judge orders FDA to hasten release of Pfizer vaccine docs
Wait what? FDA wants 55 years to process FOIA request over vaccine data
Reporting by Mike Scarcella
Aset Terkait
Berita Terbaru
Pengungkapan: Entitas XM Group menyediakan layanan khusus eksekusi dan akses ke Fasilitas Trading Online kami, yang memungkinkan Anda untuk melihat dan/atau menggunakan konten yang tersedia pada atau melalui situs, yang tidak untuk mengubah atau memperluas, serta tidak mengubah atau memperluas hal tersebut. Akses dan penggunaan ini selalu sesuai dengan: (i) Syarat dan Ketentuan; (ii) Peringatan Risiko; dan (iii) Pengungkapan Penuh. Oleh karena itu, konten disediakan hanya sebagai informasi umum. Anda juga harus ketahui bahwa konten Fasilitas Trading Online kami bukan sebagai ajakan atau tawaran untuk untuk melakukan transaksi apa pun di pasar finansial. Trading di pasar finansial mana pun melibatkan tingkat risiko yang signifikan pada modal Anda.
Semua materi yang diterbitkan di Fasilitas Trading Online kami hanya untuk tujuan edukasi/informasi dan tidak boleh mengandung nasihat dan rekomendasi finansial, pajak investasi atau trading, catatan harga trading kami, penawaran, permintaan, transaksi dalam instrumen finansial apa pun atau promo finansial untuk Anda yang tidak diminta.
Konten pihak ketiga apa pun, serta konten yang disiapkan oleh XM, seperti opini, berita, riset, analisis, harga, informasi lain atau link ke situs pihak ketiga yang tersedia "sebagaimana adanya", sebagai komentar pasar umum dan bukan menjadi nasihat investasi. Sejauh konten apa pun ditafsirkan sebagai penelitian investasi, Anda harus memperhatikan dan menerima bahwa konten tersebut tidak dimaksudkan dan belum disiapkan sesuai dengan persyaratan hukum yang dirancang untuk mempromosikan kemandirian riset investasi dan dengan demikian akan dianggap sebagai komunikasi pemasaran di bawah hukum dan peraturan yang relevan. Mohon dipastikan bahwa Anda telah membaca dan memahami Notifikasi pada Riset Investasi Non-Independen dan Peringatan Risiko kami mengenai informasi di atas, yang dapat diakses disini.
